Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill hopes to slow rare brain disease MSA

NCT ID NCT06568237

Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests an experimental oral drug, TEV-56286, in 350 adults with multiple system atrophy (MSA), a rare and progressive brain disorder. Participants will receive either the drug or a placebo for 48 weeks to see if it slows disease worsening and is safe. The goal is to find a treatment that helps control MSA symptoms and progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * is considered to be "clinically possible" or "clinically probable" MSA as determined by the Gilman criteria * is medically and psychiatrically stable, as indicated by medical and psychiatric history, as well as physical and neurological examination * Females of child bearing potential (CBP) may be included only if they have a negative pregnancy test at the screening and baseline visits * Females of CBP whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods * Males who are potentially fertile/reproductively competent (not surgically \[eg, vasectomy\] or congenitally sterile) and their female partners who are of CBP must use, together with their female partners, highly effective birth control methods * Additional criteria apply; please contact the investigator for more information Exclusion Criteria: * has 2 or more relatives with history of MSA, suggestive of an alternative diagnosis other than MSA * has participated in another clinical study involving administration of an IMP within 3 months or 5 half-lives (whichever is longer) of this IMP prior to screening * has a history of, or acknowledges, alcohol or other substance abuse in the 12 months before screening * is a female participant who is pregnant or breastfeeding, or plans to become pregnant during the study * has a known hypersensitivity to any components of the IMP * is of a vulnerable population (eg, people kept in detention or jail) * participant is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this study * Additional criteria apply; please contact the investigator for more information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple system atrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple system atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple system atrophy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    57 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Teva Investigational Site 15543

    ACTIVE_NOT_RECRUITING

    Spokane, Washington, 99202, United States

  • Teva Investigational Site 15544

    ACTIVE_NOT_RECRUITING

    Boca Raton, Florida, 33486, United States

  • Teva Investigational Site 15545

    NOT_YET_RECRUITING

    Los Angeles, California, 90095, United States

  • Teva Investigational Site 15546

    RECRUITING

    Kansas City, Kansas, 66160, United States

  • Teva Investigational Site 15547

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

  • Teva Investigational Site 15548

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • Teva Investigational Site 15549

    RECRUITING

    New York, New York, 10016, United States

  • Teva Investigational Site 15550

    RECRUITING

    Chicago, Illinois, 60612-3852, United States

  • Teva Investigational Site 15551

    RECRUITING

    New York, New York, 10032-3726, United States

  • Teva Investigational Site 15552

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Teva Investigational Site 15553

    ACTIVE_NOT_RECRUITING

    Durham, North Carolina, 27705-4410, United States

  • Teva Investigational Site 15554

    RECRUITING

    La Jolla, California, 92037, United States

  • Teva Investigational Site 15555

    RECRUITING

    Tampa, Florida, 33613, United States

  • Teva Investigational Site 15735

    NOT_YET_RECRUITING

    Hershey, Pennsylvania, 17033, United States

  • Teva Investigational Site 15736

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Teva Investigational Site 15869

    NOT_YET_RECRUITING

    Georgetown, Texas, 78628, United States

  • Teva Investigational Site 15870

    NOT_YET_RECRUITING

    Farmington Hills, Michigan, 48334, United States

  • Teva Investigational Site 15873

    ACTIVE_NOT_RECRUITING

    Alexandria, Virginia, 22310, United States

  • Teva Investigational Site 15874

    RECRUITING

    Nashville, Tennessee, 37212, United States

  • Teva Investigational Site 30294

    RECRUITING

    Padova, 35127, Italy

  • Teva Investigational Site 30295

    RECRUITING

    Salerno, 84131, Italy

  • Teva Investigational Site 30296

    RECRUITING

    Roma, 00163, Italy

  • Teva Investigational Site 30297

    RECRUITING

    Catania, 95123, Italy

  • Teva Investigational Site 30298

    RECRUITING

    Milan, 20132, Italy

  • Teva Investigational Site 30299

    RECRUITING

    Bologna, 40139, Italy

  • Teva Investigational Site 31319

    RECRUITING

    Valencia, 46026, Spain

  • Teva Investigational Site 31320

    RECRUITING

    Pamplona, 31008, Spain

  • Teva Investigational Site 31321

    RECRUITING

    Barcelona, 08036, Spain

  • Teva Investigational Site 31322

    RECRUITING

    Seville, 41015, Spain

  • Teva Investigational Site 31323

    RECRUITING

    Barcelona, 08035, Spain

  • Teva Investigational Site 31324

    RECRUITING

    Barcelona, 08041, Spain

  • Teva Investigational Site 31327

    RECRUITING

    Madrid, 28006, Spain

  • Teva Investigational Site 31328

    RECRUITING

    Barakaldo, 48903, Spain

  • Teva Investigational Site 31329

    RECRUITING

    Elche, 03203, Spain

  • Teva Investigational Site 31330

    RECRUITING

    Madrid, 28034, Spain

  • Teva Investigational Site 31331

    RECRUITING

    Madrid, 28041, Spain

  • Teva Investigational Site 32818

    RECRUITING

    Dresden, 01307, Germany

  • Teva Investigational Site 32819

    RECRUITING

    Münster, 48149, Germany

  • Teva Investigational Site 32820

    RECRUITING

    München, 81377, Germany

  • Teva Investigational Site 32821

    RECRUITING

    Ulm, 89081, Germany

  • Teva Investigational Site 32822

    RECRUITING

    Düsseldorf, 40225, Germany

  • Teva Investigational Site 32823

    RECRUITING

    Beelitz, 14547, Germany

  • Teva Investigational Site 32824

    RECRUITING

    Marburg, 35033, Germany

  • Teva Investigational Site 32825

    RECRUITING

    Kassel, 34128, Germany

  • Teva Investigational Site 32826

    RECRUITING

    Leipzig, 04103, Germany

  • Teva Investigational Site 35289

    RECRUITING

    Marseille, 13385, France

  • Teva Investigational Site 35290

    RECRUITING

    Bordeaux, 33400, France

  • Teva Investigational Site 35291

    RECRUITING

    Paris, 75651 Cedex 13, France

  • Teva Investigational Site 35292

    RECRUITING

    Toulouse, 31059, France

  • Teva Investigational Site 35300

    RECRUITING

    Caen, 14033, France

  • Teva Investigational Site 61808

    RECRUITING

    Belgrade, 11000, Serbia

  • Teva Investigational Site 80203

    RECRUITING

    Haifa, 31999, Israel

  • Teva Investigational Site 80204

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Teva Investigational Site 80215

    RECRUITING

    Jerusalem, 9103102, Israel

  • Teva Investigational Site 84135

    RECRUITING

    Sendai, 982-8555, Japan

  • Teva Investigational Site 84136

    RECRUITING

    Gifu, 501-1112, Japan

  • Teva Investigational Site 84137

    RECRUITING

    Niigata, 951-8520, Japan

  • Teva Investigational Site 84138

    RECRUITING

    Sagamihara, 252-0392, Japan

  • Teva Investigational Site 84139

    RECRUITING

    Fuchū, 183-0042, Japan

  • Teva Investigational Site 84140

    RECRUITING

    Chiba, 260-8677, Japan

  • Teva Investigational Site 84141

    RECRUITING

    Sanda-shi, 669-1592, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.